Patents by Inventor Haim Aviv

Haim Aviv has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20120156185
    Abstract: The present invention provide edible compositions comprising soluble and insoluble dietary fibers at a ratio of about 1:1 ratio, having a palatable taste, useful for reducing the serum lipid content in a mammal, and further for reducing the blood glucose level, enhancing the feeling of satiety and keeping a desired body weight.
    Type: Application
    Filed: August 31, 2010
    Publication date: June 21, 2012
    Applicant: HERBAMED LTD.
    Inventors: Anat Solomon, Haim Aviv
  • Publication number: 20070060636
    Abstract: The present invention relates to a synthetic cannabinoid, dexanabinol, of enantiomeric purity in excess of 99.90%, or to a pharmaceutically acceptable salt, ester or solvate of said compound. The present invention also relates to pharmaceutical grade compositions comprising said compound of high enantiomeric purity, and uses thereof for prevention and treatment of neurological disorders, chronic degenerative diseases, CNS poisoning, cognitive impairment, inflammatory diseases or disorders, autoimmune diseases or disorders, pain, emesis, glaucoma and wasting syndromes.
    Type: Application
    Filed: August 14, 2006
    Publication date: March 15, 2007
    Inventors: Haim Aviv, Raphael Bar, Michael Schickler, Shimon Amselem
  • Publication number: 20040110827
    Abstract: The present invention relates to a synthetic cannabinoid, dexanabinol, of enantiomeric purity in excess of 99.90%, or to a pharmaceutically acceptable salt, ester or solvate of said compound. The present invention also relates to pharmaceutical grade compositions comprising said compound of high enantiomeric purity, and uses thereof for prevention and treatment of neurological disorders, chronic degenerative diseases, CNS poisoning, cognitive impairment, inflammatory diseases or disorders, autoimmune diseases or disorders, pain, emesis, glaucoma and wasting syndromes.
    Type: Application
    Filed: August 19, 2003
    Publication date: June 10, 2004
    Inventors: Haim Aviv, Raphael Bar, Michael Schickler, Shimon Amselem
  • Patent number: 6229003
    Abstract: The present invention relates to strains of E coli adapted to produce bovine growth hormone, being the result of extraction of RNA from bovine pituitaries, transcription of DNA on such RNA templates, splicing of DNA into plasmids, insertion of spliced plasmid into microorganisms, and further subjecting the microorganisms to selection and isolating the colonies producing the desired fused or modified growth hormone and to modified bovine growth hormone obtained by the cultivation of such modified E. coli strains and recovery of the desired product.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: May 8, 2001
    Assignee: Yeda Research and Development Company Ltd.
    Inventors: Haim Aviv, Eliyahu Keshet, Marian Gorecki, Arie Rosner
  • Patent number: 6113921
    Abstract: The present invention relates to a delivery system which includes a bioactive drug or cosmetic substance presented in the form of submicron oil spheres alone, or drugs or cosmetic substances in a combination with the oil spheres in an aqueous suspension or emulsion. Optionally, a skin penetration enhancer may be included in such formulations. Such preparations achieve improved bioavailability and exert larger pharmacological effects than an equivalent dose of the drug or cosmetic formulated in conventional creams, lotions or oleaginous bases.
    Type: Grant
    Filed: January 13, 1998
    Date of Patent: September 5, 2000
    Assignee: Pharmos Corp.
    Inventors: Doron Friedman, Joseph Schwartz, Haim Aviv
  • Patent number: 6004566
    Abstract: The present invention relates to a delivery system which includes a bioactive drug or cosmetic substance presented in the form of submicron oil spheres alone, or drugs or cosmetic substances in a combination with the oil spheres in an aqueous suspension or emulsion. Optionally, a skin penetration enhancer may be included in such formulations. Such preparations achieve improved bioavailability and exert larger pharmacological effects than an equivalent dose of the drug or cosmetic formulated in conventional creams, lotions or oleaginous bases.
    Type: Grant
    Filed: March 23, 1993
    Date of Patent: December 21, 1999
    Assignee: Pharmos Corp.
    Inventors: Doron Friedman, Joseph Schwartz, Haim Aviv
  • Patent number: 5961970
    Abstract: A vaccine adjuvant composition of an oil-in-water submicron emulsion that has about 0.5 to 50% of a first component of an oil, about 0.1 to 10% of a second component of an emulsifier, about 0.05 to 5% of a nonionic surfactant, about 0.00001 to 1% of an immunogen, and an aqueous continuous phase. This submicron emulsion has a mean droplet size in the range of between about 0.03 and 0.5 .mu.m, and preferably 0.05 and 0.2 .mu.m.
    Type: Grant
    Filed: April 29, 1996
    Date of Patent: October 5, 1999
    Assignees: Pharmos Corporation, The United States of America as represented by the Secretary of the Army
    Inventors: George H. Lowell, Shimon Amselem, Doron Friedman, Haim Aviv
  • Patent number: 5716637
    Abstract: The present invention provides pharmaceutical vaccine compositions that are nanoemulsions of particles having a lipid core which is in a solid or liquid crystalline phase at 25.degree. C., and which is surrounded by at least one phospholipid bilayer for the parenteral, oral, intranasal, rectal, vaginal or topical delivery of both hydrophilic and lipophilic immunogens. The particles have a mean diameter in the range of 10 to 250 nm and the immunogen is incorporated therein, either intrinsically prior to the homogenization process or extrinsically thereafter.
    Type: Grant
    Filed: November 16, 1995
    Date of Patent: February 10, 1998
    Assignees: Pharmos Corporation, The United States of America as represented by the Secretary of the Army
    Inventors: Shimon Anselem, George H. Lowell, Haim Aviv, Doron Friedman
  • Patent number: 5670371
    Abstract: A plasmid for the production of superoxide dismutase or an analog thereof which upon introduction into a suitable bacterial host containing the thermolabile repressor C.sub.I renders the host cell capable, upon increasing the temperature of the host cell to a temperature at which the repressor is destroyed, of effecting expression of DNA encoding superoxide dismutase and production of superoxide dismutase. The plasmid is a double-stranded DNA molecule which includes in 5' to 3' order the following: a DNA sequence which contains the promoter and operator P.sub.L O.sub.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: September 23, 1997
    Assignee: Bio-Technology General Corp.
    Inventors: Haim Aviv, Marian Gorecki, Avigdor Levanon, Amos Oppenheim, Jacob Hartman
  • Patent number: 5496811
    Abstract: An ocular drug delivery vehicle of an oil-in-water submicron emulsion comprising about 0.5 to 50% of a first component of an oil, about 0.1 to 10% of a second component of an emulsifier, about 0.05 to 5% of a non-ionic surfactant and an aqueous component, with the mean droplet size being in the submicron range, i.e., below about 0.5 .mu.m and preferably between about 0.1 and 0.3 .mu.m. Also, topical pharmaceutical compositions containing a drug such as an anti-glaucoma drug, beta adrenergic blocker or other autonomic system drug, a local anesthetic, a steroid, a non-steroidal anti-inflammatory drug, an antibiotic drug, an antifungal drug, an antiviral drug or combinations thereof and the vehicle described above. Methods of administering such vehicles or compositions to the eye of a patient while reducing irritation thereof and providing increased bioavailability of the drug.
    Type: Grant
    Filed: January 5, 1993
    Date of Patent: March 5, 1996
    Assignee: Pharmos Corp.
    Inventors: Haim Aviv, Doron Friedman, Amir Bar-Ilan, Micha Vered
  • Patent number: 5457042
    Abstract: A novel analog of human superoxide dismutase which comprises the non-acetylated, non-glycosylated form of natural human superoxide dismutase having the ser-met amino acid sequence attached to the N-terminus and a mixture comprising this analog and non-acetylated, non-glycosylated superoxide dismutase having an amino acid sequence identical to that of natural human superoxide dismutase are provided. Methods of catalyzing a chemical reaction using the novel analog and mixture are provided.
    Type: Grant
    Filed: August 21, 1992
    Date of Patent: October 10, 1995
    Assignee: Bio-Technology General Corp.
    Inventors: Jacob R. Hartman, Amos B. Oppenheim, Marian Gorecki, Haim Aviv, Rachel Oren
  • Patent number: 5455029
    Abstract: An improved plasmid for the production of superoxide dismutase on an analog thereof which upon introduction into a suitable host containing the thermolabile repressor C.sub.I renders the host capable of effecting expression of a gene encoding superoxide dismutase or the analog. The plasmid is a double-stranded DNA molecule which includes in 5' to 3' order the following: the promoter and operator P.sub.L O.sub.L from lambda bacteriophage; the N utilization site; a first restriction enzyme site permitting replacement of the ribosomal binding site which follows thereafter; a ribosomal binding site; an ATG initiation codon; a second restriction enzyme site; a gene encoding superoxide dismutase or the analog; an origin of replication and a gene associated with a selectable or identifiable phenotypic trait manifested when the plasmid is present in the host. The distance between the 3' end of P.sub.L O.sub.L and the 5' end of the N utilization site is less than about 80 base pairs.
    Type: Grant
    Filed: August 21, 1992
    Date of Patent: October 3, 1995
    Assignee: Bio-Technology General Corp.
    Inventors: Jacob R. Hartman, Amos B. Oppenheim, Marian Gorecki, Haim Aviv, Rachel Oren
  • Patent number: 5256546
    Abstract: A plasmid for the production of porcine growth hormone or an analog thereof which upon introduction into a suitable bacterial host containing the thermolabile repressor C.sub.I renders the host cell capable, upon increasing the temperature of the host cell to a temperature at which the repressor is destroyed, of effecting expression of DNA encoding porcine growth hormone and production of porcine growth hormone or analogs thereof.
    Type: Grant
    Filed: February 24, 1992
    Date of Patent: October 26, 1993
    Assignee: Bio-Technology General Corp.
    Inventors: Haim Aviv, Marian Gorecki, Avigdor Levanon, Amos Oppenheim, Tikva Vogel, Elisha Zeelon, Menachem Zeevi
  • Patent number: 5198361
    Abstract: An improved vector upon introduction into a suitable bacterial host containing the thermolabile repressor C.sub.I renders the host cell capable, upon increasing the temperature of the host cell to a temperature at which the repressor is destroyed, of effecting expression of a desired gene inserted into the vector and production of polypeptide encoded by the gene. The vector is a double-stranded DNA molecule which includes in 5' to 3' order the following: a DNA sequence which contains the promoter and operator P.sub.L O.sub.
    Type: Grant
    Filed: January 3, 1991
    Date of Patent: March 30, 1993
    Assignee: Bio-Technology General Corp.
    Inventors: Haim Aviv, Marian Gorecki, Avigdor Levanon, Amos Oppenheim, Tikva Vogel, Elisha Zeelon, Menachem Zeevi
  • Patent number: 5162217
    Abstract: An improved plasmid for the production of superoxide dismutase which upon introduction into a host containing the thermolabile repressor C.sub.I renders the host capable of effecting expression of a gene encoding superoxide dismutase. The plasmid which includes in 5' to 3' order the following: the promoter and operator P.sub.L O.sub.L from lambda bacteriophage; the N utilization site; a first restriction enzyme site permitting replacement of the ribosomal binding site which follows thereafter; a ribosomal binding site; an ATG initiation codon; a second restriction enzyme site; a gene encoding superoxide dismutase; an origin of replication and a gene associated with a selectable or identifiable phenotypic trait manifested when the plasmid is present in the host. The distance between the 3' end of P.sub.L O.sub.L and the 5' end of the N utilization site is less than about 80 base pairs.
    Type: Grant
    Filed: December 8, 1989
    Date of Patent: November 10, 1992
    Assignee: Bio-Technology General Corp.
    Inventors: Jacob R. Hartman, Amos B. Oppenheim, Marian Gorecki, Haim Aviv, Rachel Oren
  • Patent number: 5143836
    Abstract: An improved plasmid for the production of superoxide dismutase which upon introduction into a host containing the thermolabile repressor C.sub.I renders the host capable of effecting expression of a gene encoding superoxide dismutase. The plasmid includes in 5' to 3' order the following: the promoter and operator P.sub.L O.sub.L from lambda bacteriophage; the N utilization site; a first restriction enzyme site permitting replacement of the ribosomal binding site which follows thereafter; a ribosomal binding site; an ATG initiation codon; a second restriction enzyme site; a gene encoding superoxide dismutase; an origin of replication and a gene associated with a selectable or identifiable phenotypic trait manifested when the plasmid is present in the host. The distance between the 3' end of P.sub.L O.sub.L and the 5' end of the N utilization site is less than about 80 base pairs.
    Type: Grant
    Filed: May 13, 1988
    Date of Patent: September 1, 1992
    Assignee: Bio-Technology General Corp.
    Inventors: Jacob R. Hartman, Amos B. Oppenheim, Marian Gorecki, Haim Aviv
  • Patent number: 4997916
    Abstract: A method is provided for recovering a purified animal growth hormone or a polypeptide analog thereof having substantially the same amino acid sequence as, and the biological activity of, the corresponding naturally-occurring animal growth hormone from a bacterial cell in which the animal growth hormone or polypeptide analog has been produced by means of expression of a plasmid encoding the hormone or polypeptide analog which comprises: (a) disrupting the cell wall of the bacterial cell in a buffered neutral pH solution so as to produce a lysate containing precipitated hormone or polypeptide analog; (b) recovering the resulting precipitated hormone or polypeptide analog; (c) suspending the precipitated hormone or polypeptide analog so recovered in distilled water; (d) treating the resulting precipitate-containing suspension with a sodium hydroxide solution having an alkaline pH of about 11.
    Type: Grant
    Filed: March 7, 1989
    Date of Patent: March 5, 1991
    Assignee: Bio-Technology General Corp.
    Inventors: Haim Aviv, Marian Gorecki, Avigdor Levanon, Amos Oppenheim, Tikva Vogel, Elisha Zeelon, Menachem Zeevi
  • Patent number: 4871835
    Abstract: Analogs of hGH having the activity of naturally occurring hGH and a similar amino acid sequence varying from the sequence of natural hGh by the addition of one or more amino acids, e.g. methione or methionine-leucine, to the N-terminus of natural hGH have been produced, recovered and purified. Such analogs may be incorporated into pharmaceutical compositions and administered to a subject to increase the level of hGH in the subject.Analogs of hGH which comprise the amino acid sequence of natural hGH from the N-terminus of which one or more amino acids have been deleted, e.g. Met.sup.14 hGh, have been produced, recovered and purified. Such analogs may be incorporated into pharmaceutical compositions and administered to a subject to lower the level of hGH in the subject.A plasmid has been constructed which directs the expression of an analog of hGH having the amino acid sequence methionine-leucine added to the N-terminus of natural hGH.
    Type: Grant
    Filed: January 14, 1985
    Date of Patent: October 3, 1989
    Assignee: Bio-Technology General Corp.
    Inventors: Haim Aviv, Marian Gorecki, Avigdor Levanon, Amos Oppenheim, Tikva Vogel, Pinhas E. Zeelon, Menachem Zeevi
  • Patent number: 4831120
    Abstract: An improved vector upon introduction into a suitable bacterial host containing the thermolabile repressor C.sub.I renders the host cell capable, upon increasing the temperature of the host cell to a temperature at which the repressor is destroyed, of effecting expression of a desired gene inserted into the vector and production of polypeptide encoded by the gene. The vector is a double-stranded DNA molecule which includes in 5' to 3' order the following: a DNA sequence which contains the promoter and operator P.sub.L O.sub.
    Type: Grant
    Filed: July 3, 1985
    Date of Patent: May 16, 1989
    Assignee: Bio-Technology General Corp.
    Inventors: Haim Aviv, Marian Gorecki, Avigdor Levanon, Amos Oppenheim, Tikva Vogel, Elisha Zeelon, Menachem Zeevi